IBC Superior for Liver Metastasis in Lung Cancer

Oct 6, 2026 · Published in: Cancer Medicine

📅 Journal publication: Oct 2026 · Last updated: Oct 8, 2026

Background Information

New treatments show promise for liver metastases in lung cancer.

Liver metastasis complicates treatment in lung adenocarcinoma; identifying effective first-line therapies is crucial for improving outcomes. IBC treatment showed higher disease control (95.6%) and prolonged median progression-free survival (8.48 months) compared to BC and IC options. Results suggest IBC may be more effective for certain subgroups, though limitations include its retrospective nature and lack of OS significance. IBC appears superior for liver metastases in lung adenocarcinoma patients with certain characteristics.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Li J, Ge Y, Liu Q, Wei X, Wang J, Wang X, Wang D, Liu J, Sun Y, Gao A

Citation: Li J, Ge Y, Liu Q, et al. Efficacy and Safety of First-Line Treatment Options for Oncogene Wild-Type Lung Adenocarcinoma With Liver Metastases. Cancer medicine. 2026;15(10):e72282. doi:10.1002/cam4.72282

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.